Google NewsTelix Pharmaceuticals (ASX:TLX) Rises as Health Care Stocks Lead the Market - Kalkine
Telix Pharmaceuticals (ASX:TLX) Rises as Health Care Stocks Lead the Market Kalkine
TELIX PHARMACEUTICAL ORDINARY (TLX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineTelix Trial Update Puts Theranostics Back in Focus
Highlights Telix reported encouraging safety data from its late-stage prostate cancer therapy trial. A new United Imaging agreement may support broader theranostic workflow development. The update strengthens attention on radiopharmaceuticals, imaging and oncology innovation. Telix reported encouraging ProstACT safety data and expanded an imaging partnership, reinforcing attention on radiopharmaceuticals, theranostics and oncology innovation across Australia’s healthcare market. Austral...
Telix Pharmaceuticals (ASX:TLX) Share Trade in Green Territory – Here’s Why - Kalkine
Telix Pharmaceuticals (ASX:TLX) Share Trade in Green Territory – Here’s Why Kalkine
Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity - Kalkine
Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity Kalkine
ASXAppendix 3Y Change in Director Interest - C Behrenbruch
director_dealing announcement
Appendix 3Y Change in Director Interest - Maria Rivas
director_dealing announcement
Appendix 3Y Change in Director Interest - W Jellison
director_dealing announcement
Appendix 3Y Change in Director Interest - M McDonald
director_dealing announcement
Appendix 3Y Change in Director Interest - David Gill
director_dealing announcement
Motley FoolWhat does a takeover in the US tell us about the value of Telix shares?
Currently there seems to be a steep discount on this stock. The post What does a takeover in the US tell us about the value of Telix shares? appeared first on The Motley Fool Australia.
Is Telix Pharmaceuticals (ASX:TLX) Entering a New Uptrend Phase on the ASX? - Kalkine
Is Telix Pharmaceuticals (ASX:TLX) Entering a New Uptrend Phase on the ASX? Kalkine
Hidden Signals in Telix Pharmaceuticals (ASX:TLX) Stock Drop That Investors Missed - Kalkine
Hidden Signals in Telix Pharmaceuticals (ASX:TLX) Stock Drop That Investors Missed Kalkine
Telix Annual General Meeting Chairman and CEO Addresses
other announcement
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones - simplywall.st
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent FDA And Pipeline Milestones simplywall.st
App 3X Initial Director Interests - W Jellison
director_dealing announcement
App 3X Initial Director Interests - M Rivas
director_dealing announcement
App 3X Initial Director Interests - D Gill
director_dealing announcement
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration - simplywall.st
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New Trial Data Plans And Regeneron Collaboration simplywall.st
Appendix 3Y Change in Director Interests - C Behrenbruch
director_dealing announcement
Webinar - A Next-Gen Portfolio Approach to PSMA Therapy
other announcement
Telix Announces Settlement of US$600M Convertible Bonds
other announcement
Is Telix Pharma (ASX:TLX) in ASX 200 Market Focus?
Highlights Telix Pharmaceuticals reflects valuation-related market attention. Biotechnology developments influence healthcare sector activity. Market participation aligns with broader ASX healthcare trends. Telix Pharmaceuticals reflects valuation-focused attention within the ASX healthcare sector, highlighting biotechnology participation and trends across ASX 100 and ASX 200 indices. The healthcare and biotechnology sector represents a vital component of the Australian equity landscape...
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch - simplywall.st
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch simplywall.st
Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon Stocks Down Under
Telix Pharmaceuticals upsizes convertible bonds to US$600 million
Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds. The post Telix Pharmaceuticals upsizes convertible bonds to US$600 million appeared first on The Motley Fool Australia.
Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances
Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance. The post Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances appeared first on The Motley Fool Australia.
Telix Successfully Prices Upsized US$600M Convertible Bonds
other announcement
Telix (ASX:TLX) Signals Fresh Growth Trajectory Amid Expanding Footprint
Highlights Strategic oncology collaboration expands pipeline reach Regulatory progress strengthens product portfolio depth Imaging and therapy platform continues to evolve Recent developments surrounding Telix Pharmaceuticals signal a shift toward broader oncology capabilities, supported by collaboration efforts and regulatory momentum in brain imaging solutions. Is Telix (TLX) Entering a New Growth Phase? Telix Pharmaceuticals (ASX:TLX) has recently drawn market attention following a n...
Telix Pharmaceuticals (ASX:TLX) Is Up 13.1% After Regeneron Tie-Up And FDA NDA Acceptance For TLX101-Px - simplywall.st
Telix Pharmaceuticals (ASX:TLX) Is Up 13.1% After Regeneron Tie-Up And FDA NDA Acceptance For TLX101-Px simplywall.st
Telix share price leaping higher today on $3 billion US news
Investors are snapping up Telix shares on Monday following big US news. The post Telix share price leaping higher today on $3 billion US news appeared first on The Motley Fool Australia.
Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure Stocks Down Under
Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal
Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies. The post Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal appeared first on The Motley Fool Australia.
Telix and Regeneron Announce Radiopharma Collaboration
other announcement
Telix Pharmaceuticals (ASX:TLX) Big Upside, but Only if the FDA Says Yes. - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) Big Upside, but Only if the FDA Says Yes. Stocks Down Under
Telix Pharmaceuticals: FDA accepts Pixclara NDA
The FDA has accepted Telix's Pixclara NDA for imaging brain cancer. The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.
Telix Strengthens Board with Further Director Appointments
other announcement